Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash & Current Investments (2016 - 2025)

Abeona Therapeutics has reported Cash & Current Investments over the past 15 years, most recently at $191.4 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $191.4 million for Q4 2025, up 95.19% from a year ago — trailing twelve months through Dec 2025 was $191.4 million (up 95.19% YoY), and the annual figure for FY2025 was $191.4 million, up 95.19%.
  • Cash & Current Investments for Q4 2025 was $191.4 million at Abeona Therapeutics, down from $207.1 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for ABEO hit a ceiling of $225.9 million in Q2 2025 and a floor of $18.2 million in Q3 2022.
  • Median Cash & Current Investments over the past 5 years was $65.3 million (2021), compared with a mean of $84.9 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 73.27% in 2022 and later soared 230.66% in 2024.
  • Abeona Therapeutics' Cash & Current Investments stood at $50.9 million in 2021, then increased by 3.09% to $52.5 million in 2022, then grew by 0.15% to $52.6 million in 2023, then surged by 86.55% to $98.1 million in 2024, then skyrocketed by 95.19% to $191.4 million in 2025.
  • The last three reported values for Cash & Current Investments were $191.4 million (Q4 2025), $207.1 million (Q3 2025), and $225.9 million (Q2 2025) per Business Quant data.